Sun Pharmaceutical’s SPARC Unit Hopes To Kindle India Research Pipeline

Sun Pharma’s research unit SPARC shared an update of its research pipeline, but analysts are short on excitement, owing mostly to delays on timelines.

MUMBAI – Cash flow uncertainty clouds the prospects for Indian drug companies to transition to a research-driven approach, as evidenced on a March 25 investor call by Sun Pharma Advanced Research Co. Ltd. (SPARC) – the carved-out, listed research entity of Sun Pharmaceutical Industries Ltd.

Delays in meeting product development and launch timelines have made investors wary about the likely upsides from the late-stage pipeline...

More from India

More from Focus On Asia